Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2

Abstract

Benralizumab achieved significantly improved asthma control in real-world patients with different blood eosinophil counts, including eosinophil counts ranging from less than 150 to greater than or equal to 300 cells/μL, switching from other biologics, or treated for up to 24 months.